

## SR Pharma - RNAi Technology Briefing

**London, UK, 21 February 2007** ..... SR Pharma plc, the Company, (London LSE: SPA), Europe's leading RNAi therapeutics company, today hosts an RNAi technology briefing for analysts at 12:30hrs at Citigate Dewe Rogerson's offices, 3 London Wall Buildings, London Wall, EC2M 5SY.

Key members of the senior management team will make presentations highlighting the potential of RNAi therapeutics and the Company's proprietary RNAi technology, which incorporates novel, chemically modified proprietary siRNA molecules ("AtuRNAi") as well as its systemic delivery system ("AtuPLEX").

For further details of the presentations given today, please contact Citigate Dewe Rogerson (contact details below).

- Ends -

### **SR Pharma ([www.srpharma.com](http://www.srpharma.com))**

SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG ([www.atugen.com](http://www.atugen.com)) based in Berlin, Germany and Stanford Rook Ltd based in London, UK.

SR Pharma is a leader in RNAi therapeutics, which is a Nobel Prize winning technology that "silences" genes linked to the onset of disease. The Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi"), which have a number of advantages over conventional siRNA molecules including enhanced stability against nuclease degradation. In addition, the Company has developed a proprietary delivery system ("AtuPLEX"), which increases bioavailability, circulation times and functional intracellular uptake of siRNA molecules.

SR Pharma expects to begin the clinical development of its proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2007. SR Pharma has sublicensed the AtuRNAi compound RTP-801i to Pfizer through its collaboration partner Quark Biotech Inc. for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. The lead programme entered into Phase I trials for AMD in early 2007. In addition SR Pharma has licensed a further AtuRNAi compound, PFTi, to Quark Biotech Inc., which should enter clinical trials for acute renal failure in 2007.

SR Pharma also owns a proprietary Mycobacterium vaccae-based technology and related products. Currently the Company is in discussions with third parties regarding the co-development and out-licensing of these products.

### **Forward-Looking Statements**

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to SR Pharma and SR Pharma assumes no obligation to update any such forward-looking statements.

### **Enquiries:**

For further information, please contact the following:

**SR Pharma plc**  
+44(0)20 7307 1620  
Iain Ross, Chairman  
Melvyn Davies, Finance Director

**Citigate Dewe Rogerson**  
+44(0)20 7638 9571  
David Dible  
Yvonne Alexander  
Valerie Auffray

**Atugen AG**

+49(0)30 9489 2800

Thomas Christély, Chief Executive Officer

Dr. Klaus Giese, Chief Scientific Officer